Comparative Pharmacology
Head-to-head clinical analysis: LIPOSYN II 10 versus LIPOSYN III 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIPOSYN II 10 versus LIPOSYN III 30.
LIPOSYN II 10% vs LIPOSYN III 30%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential fatty acids (linoleic and linolenic) and calories for patients requiring parenteral nutrition; fatty acids are incorporated into cell membranes and serve as precursors for prostaglandins.
Liposyn III 30% is a lipid emulsion providing essential fatty acids (linoleic and linolenic acids) and calories for parenteral nutrition. It serves as a substrate for energy production and component of cell membranes.
Intravenous infusion; maximum daily dose of 2.5 g/kg (25 mL/kg) provided as part of parenteral nutrition, typically administered over 12-24 hours.
Adults: 1-2 g/kg/day intravenously, not to exceed 2.5 g/kg/day. Initial rate 0.5-1 mL/min for first 30 minutes, increase to 100-125 mL/h as tolerated.
None Documented
None Documented
18–24 hours for clearance of infused triglycerides; terminal elimination half-life of soybean oil emulsion particles is approximately 30 minutes for particles <1 µm, but longer for larger particles (up to several hours); clinical context: prolonged half-life in renal/hepatic impairment.
The terminal elimination half-life of the triglyceride component is approximately 30 minutes (range 20-40 minutes) in patients with normal lipid metabolism. In critically ill patients or those with impaired clearance, half-life may be prolonged.
Renal: negligible; biliary/fecal: negligible; metabolized in tissues (e.g., muscle, adipose) via beta-oxidation and re-esterification; CO2 production via tricarboxylic acid cycle accounts for majority of elimination.
Liposyn III 30% is a fat emulsion; its components are metabolized like endogenous triglycerides. Clearance involves hydrolysis by lipoprotein lipase, releasing free fatty acids which are oxidized or stored. Less than 1% is excreted unchanged in urine; a small fraction is excreted in bile/feces. No significant renal or biliary elimination of intact emulsion.
Category C
Category C
Intravenous Fat Emulsion
Intravenous Fat Emulsion